Anti-Chikungunya Virus (Clone: CHKV-35) – Low Endotoxin Functional Formulation

Home/Infectious Diseases, Monoclonal Antibodies, Primary Monoclonal Antibodies, Recombinant Antibodies/Anti-Chikungunya Virus (Clone: CHKV-35) – Low Endotoxin Functional Formulation

Pricing & Details

Product No.LT569
Clone
CHKV-35
Protein
Chikungunya E2 Protein
Formats AvailableView All
Product Type
Recombinant Monoclonal Antibody
Alternate Names
CHIKV
Isotype
Human IgG1
Applications
ELISA
,
N
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT569-250 µg
250 µg
$390.00
Pre-order
Max:
Min: 1
Step: 1
LT569-1.0 mg
1.0 mg
$1,400.00
Pre-order
Max:
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Chikungunya
Virus
Expression Host
HEK-293
Immunogen
B cells of a survivor of natural CHIKV infection
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
ELISA
N
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
The monoclonal antibody clone CHKV-35 binds to and neutralizes CHIKV vaccine strain 181/25
Antigen Distribution
The E2 Envelope protein is expressed on the surface of the Chikungunya Virus
Background
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics globally and has been declared a notable disease by the CDC1,2. Symptoms include high fever, myalgia, rash, and severe polyarthritis which can persist for long after acute infection. CHIKV is an enveloped virus with an 11.8-kb single-stranded, positive-sense RNA genome with two open reading frames3,4. There are three main genotypes, having 95.2 to 99.8% amino acid identity: Asian, West African, and East/Central/South African (ECSA). The mature CHIKV virion is comprised of a nucleocapsid protein C and two glycoproteins, E1 and E25. E1 participates in virus fusion. E2 functions in attachment to cells. E1 and E2 form 80 trimeric spikes on the virus surface6.

Co-circulation of CHIKV with other arboviruses, such as dengue, Zika, Mayaro, and yellow fever, occurs in many countries, posing significant difficulties for diagnosis2. Monoclonal antibodies (MAb) can be used both for diagnosis7 and as a therapeutic agent5,8,9. CHIKV can be rapidly detected by an immunochromatographic assay using MAbs against the CHIKV envelope protein7.

CHKV-35 was generated from peripheral blood mononuclear cells from an immune donor by Epstein-Barr Virus transformation followed by hybridoma generation10. CHKV-35 binds to and neutralizes CHIKV vaccine strain 181/25.

Antigen Details

Research Area
Chikungunya
.
Infectious Disease
.
Viral

References & Citations

1. Barrera, R., Hunsperger, E., Lanciotti, RS. et al. Preparedness and response for chikungunya virus introduction in the Americas. Pan American Health Organization; National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases. 2011.
2. Silva, JVJ Jr., Ludwig-Begall, LF., Oliveira-Filho, EF. et al. Acta Trop. 188:213-224. 2018.
3. Powers, AM., Brault, AC., Tesh, RB. et al. J. Gen. Virol. 81:471–479. 2000.
4. Arankalle, VA., Shrivastava, S., Cherian, S. et al. J. Gen. Virol. 88:1967–1976. 2007.
5. Pal, P., Dowd, KA., Brien, JD. et al. PLoS Pathog. 9(4):e1003312. 2013.
6. Mukhopadhyay, S., Zhang, W., Gabler, S. et al. Structure. 14(1):63-73. 2006.
7. Okabayashi, T., Sasaki, T., Masrinoul, P. et al. J Clin Microbiol. 53(2):382-388. 2015.
8. Hawman, DW., Stoermer, KA., Montgomery, SA. et al. J Virol. 87(24):13878-13888. 2013.
9. Pal, P, Fox, JM., Hawman, DW. et al. J Virol. 88(15):8213-8226. 2014.
10. Kose N, Fox JM, Sapparapu G, et al. Sci Immunol. 4(35):eaaw6647. 2019.
Elisa Sandwich Protocol

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok